Skip to main content
SpringerLink
Log in

Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen

  • Review
  • Published:
Journal of Biomedical Science

Abstract

Hepatitis B virus surface antigen (HBsAg) vaccination has been shown to be effective in preventing hepatitis B virus (HBV) infection. The protection is based on the induction of anti-HBs antibodies against a major cluster of antigenic epitopes of HBsAg, defined as the ‘a’ determinant region of small HBsAg. Prophylaxis of recurrent HBV infection in patients who have undergone liver transplantation for hepatitis B-related end-stage liver disease is achieved by the administration of hepatitis B immune globulins (HBIg) derived from HBsAg-vaccinated subjects. The anti-HBs-mediated immune pressure on HBV, however, seems to go along with the emergence and/or selection of immune escape HBV mutants that enable viral persistence in spite of adequate antibody titers. These HBsAg escape mutants harbor single or double point mutations that may significantly alter the immunological characteristics of HBsAg. Most escape mutations that influence HBsAg recognition by anti-HBs antibodies are located in the second ‘a’ determinant loop. Notably, HBsAg with an arginine replacement for glycine at amino acid 145 is considered the quintessential immune escape mutant because it has been isolated consistently in clinical samples of HBIg-treated individuals and vaccinated infants of chronically infected mothers. Direct binding studies with monoclonal antibodies demonstrated a more dramatic impact of this mutation on anti-HBs antibody recognition, compared with other point mutations in this antigenic domain. The clinical and epidemiological significance of these emerging HBsAg mutants will be a matter of research for years to come, especially as data available so far document that these mutants are viable and infectious strains. Strategies for vaccination programs and posttransplantation prophylaxis of recurrent hepatitis need to be developed that may prevent immune escape mutant HBV from spreading and to prevent these strains from becoming dominant during the next decennia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 8(suppl):S74-S80;1990.

    Article  PubMed  Google Scholar 

  2. Ashton-Rickardt PG, Murray K. Mutations that change the immunological subtype of hepatitis B virus surface antigen and distinguish between antigenic and immunogenic determination. J Med Virol 29:204–214;1989.

    PubMed  Google Scholar 

  3. Beasley RP, Hwang LY. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 4:113–121;1984.

    PubMed  Google Scholar 

  4. Blum HE. Variants of hepatitis B, C and D viruses: Molecular biology and clinical significance. Digestion 56:85–95;1995.

    PubMed  Google Scholar 

  5. Bock TC, Torresi J, Tillmann HL, Locarnini SA, Manns MP. Replication fitness of hepatitis B virus polymerase mutants after antiviral treatment following liver transplantation. Hepatology 30:199A;1999.

  6. Brind A, Jiang J, Samuel D, Gigou M, Feray C, Brechot C, Kremsdorf D. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 26:228–235;1997.

    Article  PubMed  Google Scholar 

  7. Brown JL, Carman WF, Thomas HC. The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology 15:144–148;1992.

    PubMed  Google Scholar 

  8. Bruce SA, Murray K. Mutations of some critical amino acid residues in the hepatitis B virus surface antigen. J Med Virol 46:157–161;1995.

    PubMed  Google Scholar 

  9. Carman WF. Molecular variants of hepatitis B virus. Clin Lab Med 16:407–428;1996.

    PubMed  Google Scholar 

  10. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4(suppl 1):11–20;1997.

    PubMed  Google Scholar 

  11. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 345:1406–1407;1995.

    PubMed  Google Scholar 

  12. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, Waters J, Kliem V, Muller R, Thomas HC, Manns MP. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 24:489–493;1996.

    PubMed  Google Scholar 

  13. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325–329;1990.

    Article  PubMed  Google Scholar 

  14. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855–1859;1997.

    PubMed  Google Scholar 

  15. Chen YC, Delbrook K, Dealwis C, Mimms L, Mushahwar IK, Mandecki W. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci USA 93:1997–2001;1996.

    PubMed  Google Scholar 

  16. Chiou HL, Lee TS, Kuo J, Mau YC, Ho MS. Altered antigenicity of ‘a’ determinant variants of hepatitis B virus. J Gen Virol 78:2639–2645;1997.

    PubMed  Google Scholar 

  17. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 99:1472–1477;1997.

    PubMed  Google Scholar 

  18. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29–60;1995.

    Article  PubMed  Google Scholar 

  19. Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS. Incidence of hepatitis B virus infection in the United States, 1976–1994: Estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 178:954–959;1998.

    PubMed  Google Scholar 

  20. Cooreman MP, van Roosmalen MH, te Morsche R, Sunnen CM, de Ven EM, Jansen JB, Tytgat GN, de Wit PL, Paulij WP. Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring ‘a’ loop escape mutations. Hepatology 30:1287–1292;1999.

    Article  PubMed  Google Scholar 

  21. Cooreman MP, Sunnen CM, Verhoye L, van Roosmalen MH, Paulij WP, Leroux-Roels G. Reactivity pattern of a human monoclonal antibody against recombinant hepatitis B vaccine to HBsAg immune escape mutants. Gastroenterology 118:A1004;2000.

  22. Fischer L, Sterneck M, Muller-Ruchholtz C, Gish R, Will H. Hepatitis B virus variants associated with clinically severe recurrence after liver transplantation. Transplant Proc 31:492–493;1999.

    Article  PubMed  Google Scholar 

  23. Fortuin M, Karthigesu V, Allison L, Howard C, Hoare S, Mendy M, Whittle HC. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 169:1374–1376;1994.

    PubMed  Google Scholar 

  24. Fujii H, Moriyama K, Sakamoto N, Kondo T, Yasuda K, Hiraizumi Y, Yamazaki M, Sakaki Y, Okochi K, Nakajima E. Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus. Biochem Biophys Res Commun 184:1152–1157;1992.

    PubMed  Google Scholar 

  25. Gerin JL, Alexander H, Shih JW, Purcell RH, Dapolito G, Engle R, Green N, Sutcliffe JG, Shinnick TM, Lerner RA. Chemically synthesized peptides of hepatitis B surface antigen duplicate the d/y specificities and induce subtype-specific antibodies in chimpanzees. Proc Natl Acad Sci USA 80:2365–2369;1983.

    PubMed  Google Scholar 

  26. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213–222;1998.

    Article  PubMed  Google Scholar 

  27. Grethe S, Monazahian M, Bohme I, Thomssen R. Characterization of unusual escape variants of hepatitis B virus isolated from a hepatitis B surface antigen-negative subject. J Virol 72:7692–7696;1998.

    PubMed  Google Scholar 

  28. Guerrero E, Gavilanes F, Peterson DL. Model for the protein arrangement in HBsAg particles based on physical and chemical studies. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease 606–613;1988.

  29. Hawkins AE, Gilson RJ, Gilbert N, Wreghitt TG, Gray JJ, Ahlers-de Boer I, Tedder RS, Alexander GJ. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 24:8–14;1996.

    Article  PubMed  Google Scholar 

  30. Hino K, Katoh Y, Vardas E, Schoub B, Carman WF, Okita K. The effect of introduction of universal childhood vaccination on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants in a developing country. Hepatology 30:300A;1999.

  31. Hou J, Karayiannis P, Waters J, Luo K, Liang C, Thomas HC. A unique insertion in the S gene of surface antigen-negative hepatitis B virus Chinese carriers. Hepatology 21:273–278;1995.

    Article  PubMed  Google Scholar 

  32. Howard CR. The structure of hepatitis B envelope and molecular variants of hepatitis B virus. J Viral Hepat 2:165–170;1995.

    PubMed  Google Scholar 

  33. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30:1312–1317;1999.

    Article  PubMed  Google Scholar 

  34. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 26:786–791;1997.

    PubMed  Google Scholar 

  35. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 31:1037–1044;2000.

    Article  PubMed  Google Scholar 

  36. Iwarson S, Tabor E, Thomas HC, Goodall A, Waters J, Snoy P, Shih JW, Gerety RJ. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: An experimental study in the chimpanzee. J Med Virol 16:89–96;1985.

    PubMed  Google Scholar 

  37. Jilg W. Novel hepatitis B vaccines. Vaccine 16(suppl):S65-S68;1998.

    Article  PubMed  Google Scholar 

  38. Karthigesu VD, Allison LM, Fortuin M, Mendy M, Whittle HC, Howard CR. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 75:443–448;1994.

    PubMed  Google Scholar 

  39. Lai ME, Farci P, Figus A, Balestrieri A, Arnone M, Vyas GN. Hepatitis B virus DNA in the serum of Sardinian blood donors negative for the hepatitis B surface antigen. Blood 73:17–19;1989.

    PubMed  Google Scholar 

  40. Lau JY, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJ, Williams R. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 102:956–962;1992.

    PubMed  Google Scholar 

  41. Lee PI, Chang LY, Lee CY, Huang LM, Chang MH. Detection of hepatitis B surface gene mutation in carrier children with or without immunoprophylaxis at birth. J Infect Dis 176:427–430;1997.

    PubMed  Google Scholar 

  42. Lee PI, Lee CY, Huang LM, Chen JM, Chang MH. A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants. Vaccine 13:1685–1689;1995.

    Article  PubMed  Google Scholar 

  43. Lee WM. Hepatitis B virus infection. N Engl J Med 337:1733–1745;1997.

    Article  PubMed  Google Scholar 

  44. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 336:196–204;1997.

    Article  PubMed  Google Scholar 

  45. Mangold CM, Unckell F, Werr M, Streeck RE. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology 211:535–543;1995.

    Article  PubMed  Google Scholar 

  46. Mangold CM, Unckell F, Werr M, Streeck RE. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch Virol 142:2257–2267;1997.

    Article  PubMed  Google Scholar 

  47. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. 1984. Biotechnology 24:500–502;1992.

    PubMed  Google Scholar 

  48. McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpin MD, Nadler PI, Ostberg L. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 15:757–766;1992.

    PubMed  Google Scholar 

  49. Muller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 13:90–96;1991.

    Article  PubMed  Google Scholar 

  50. Ngui SL, O'Connell S, Eglin RP, Heptonstall J, Teo CG. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 176:1360–1365;1997.

    PubMed  Google Scholar 

  51. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 198:489–503;1994.

    Article  PubMed  Google Scholar 

  52. Ogata N, Zanetti AR, Yu M, Miller RH, Purcell RH. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 175:511–523;1997.

    PubMed  Google Scholar 

  53. Ohba K, Mizokami M, Ohno T, Suzuki K, Orito E, Lau JY, Ina Y, Ikeo K, Gojobori T. Relationships between serotypes and genotypes of hepatitis B virus: Genetic classification of HBV by use of surface genes. Virus Res 39:25–34;1995.

    Article  PubMed  Google Scholar 

  54. Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 57:231–236;1987.

    PubMed  Google Scholar 

  55. Okamoto H, Yano K, Nozaki Y, Matsui A, Miyazaki H, Yamamoto K, Tsuda F, Machida A, Mishiro S. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res 32:264–268;1992.

    PubMed  Google Scholar 

  56. Oon CJ, Chen WN. Current aspects of hepatitis B surface antigen mutants in Singapore. J Viral Hepat 5(suppl 2):17–23;1998.

    Article  PubMed  Google Scholar 

  57. Oon CJ, Lim GK, Ye Z, Goh KT, Tan KL, Yo SL, Hopes E, Harrison TJ, Zuckerman AJ. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13:699–702;1995.

    Article  PubMed  Google Scholar 

  58. Oon CJ, Ning CW, Shiuan K, Keow LG. Identification of hepatitis B surface antigen variants with alterations outside the ‘a’ determinant in immunized Singapore infants. J Infect Dis 179:259–263;1999.

    Article  PubMed  Google Scholar 

  59. Paulij WP, de Wit PL, Sunnen CM, van Roosmalen MH, Petersen-van Ettekoven A, Cooreman MP, Heijtink RA. Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. J Gen Virol 80:2121–2126;1999.

    PubMed  Google Scholar 

  60. Poirriez J. Is the strategy of universal hepatitis B vaccination necessary in low-endemic countries? Scand J Gastroenterol 33:897–899;1998.

    Article  PubMed  Google Scholar 

  61. Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, Sagliocca L, Pasquali M, Tanzi E, Longo G, Raimondo G. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology 26:495–499;1997.

    Article  PubMed  Google Scholar 

  62. Prange R, Mangold CM, Hilfrich R, Streeck RE. Mutational analysis of HBsAg assembly. Intervirology 38:16–23;1995.

    PubMed  Google Scholar 

  63. Pride MW, Thanavala YM, Strick N, Houghten RA, Neurath AR. Toleration of amino acid substitutions within hepatitis B virus envelope protein epitopes established by peptide replacement set analysis. II. Region S(122–136). Pept Res 5:217–226;1992.

    PubMed  Google Scholar 

  64. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, Neuhaus P, Gerken G. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254–263;1998.

    Article  PubMed  Google Scholar 

  65. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329:1842–1847;1993.

    Article  PubMed  Google Scholar 

  66. Sterneck M, Gunther S, Gerlach J, Naoumov NV, Santantonio T, Fischer L, Rogiers X, Greten H, Williams R, Will H. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. J Hepatol 26:754–764;1997.

    Article  PubMed  Google Scholar 

  67. Stirk HJ, Thornton JM, Howard CR. A topological model for hepatitis B surface antigen. Intervirology 33:148–158;1992.

    PubMed  Google Scholar 

  68. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28:555–561;1998.

    Article  PubMed  Google Scholar 

  69. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, Oldhafer K, Bruns I, Gauthier J, Condreay LD, Raab HR, Manns MP. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 30:244–256;1999.

    Article  PubMed  Google Scholar 

  70. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 317:489–495;1985.

    Article  PubMed  Google Scholar 

  71. Trautwein C, Schrem H, Tillmann HL, Kubicka S, Walker D, Boker KH, Maschek HJ, Pichlmayr R, Manns MP. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology 24:482–488;1996.

    PubMed  Google Scholar 

  72. Waters JA, Brown SE, Steward MW, Howard CR, Thomas HC. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 22:1–12;1992.

    Article  PubMed  Google Scholar 

  73. Waters JA, O'Rourke SM, Richardson SC, Papaevangelou G, Ghomas HC. Qualitative analysis of the humoral immune response to the ‘a’ determinant of HBs antigen after inoculation with plasma-derived or recombinant vaccine. J Med Virol 21:155–160;1987.

    PubMed  Google Scholar 

  74. Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J, Allison L, Howard C, Hall A. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 345:1089–1092;1995.

    Article  PubMed  Google Scholar 

  75. Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: A cause for concern? Vaccine 17:973–978;1999.

    Article  PubMed  Google Scholar 

  76. Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, Miyakawa Y, Mayumi M. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 68:2671–2676;1994.

    PubMed  Google Scholar 

  77. Zhang YY, Nordenfelt E, Hansson BG. Increasing heterogeneity of the ‘a’ determinant of HBsAg found in the presumed late phase of chronic hepatitis B virus infection. Scand J Infect Dis 28:9–15;1996.

    PubMed  Google Scholar 

  78. Zuckerman AJ. Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet 355:1382–1384;2000.

    Article  PubMed  Google Scholar 

  79. Zuckerman AJ, Harrison TJ, Oon CJ. Mutations in S region of hepatitis B virus (letter). Lancet 343:737–738;1994.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bioscience and Chemistry, Organon Teknika, Boxtel, The Netherlands

    Wilma P. Paulij

  2. Center for Vaccinology, Ghent University, Ghent, Belgium

    Geert Leroux-Roels

  3. Department of Gastroenterology and Hepatology Academic Medical Center, University of Amsterdam, Meibergdreef 9, NL-1105 AZ, Amsterdam, The Netherlands

    Michael P. Cooreman

Authors
  1. Michael P. Cooreman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geert Leroux-Roels
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wilma P. Paulij
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooreman, M.P., Leroux-Roels, G. & Paulij, W.P. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 8, 237–247 (2001). https://doi.org/10.1007/BF02256597

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02256597

Key Words

Search

Navigation